drugset
drugset / Trial / NCT04536532

Evaluation HEC121120 Tolerance in Healthy Subjects and Patients With Chronic Hepatitis B, Pharmacokinetics Characteristics and Antiviral Activity of Ⅰ Phase of Study

NCT04536532 ↗

Phase 1/2 Terminated 52 enrolled Sunshine Lake Pharma Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The Safety, Tolerability, Pharmacokinetics and antiviral activity Study of Anti hepatitis B virus treatment drug HEC121120 in Healthy subjects and in patients with chronic hepatitis B

Timeline

Start
2020-10-09
Primary completion
2023-03-12
Completion
2023-03-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Entecavir Small molecule 0.5 mg Oral
Subject HEC121120 Unknown 25 mg Oral
Subject HEC121120 Unknown 50 mg Oral
Subject HEC121120 Unknown 100 mg Oral
Subject HEC121120 Unknown 200 mg Oral
Subject HEC121120 Unknown 400 mg Oral
Subject HEC121120 Unknown 600 mg Oral
Subject HEC121120 Unknown 800 mg Oral

Indications

chronic hepatitis B virus infection